IVIG Market By Application 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

IVIG Market
IVIG Market: By Application (Hypogammaglobulinemia, CIDP, Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome), By Route of Administration (Intravenous, Subcutaneous), By Geography-Forecast (2016-2021)
Report Code : HCR 0233
Published: 26 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Immunoglobulin refers to the breakdown of blood plasma that contains antibody and Intravenous immunoglobulin (IVIG) can be defined as a blood product administered intravenously. This therapy applicable for individuals who cannot produce adequate amount of antibodies. Intravenous immunoglobulin therapy helps patients with common variable immunodeficiency, Wiskott Aldrich Syndrome, X-linked agammaglobulinemia and other forms of hypogammaglobulinemia.

This report identifies the intravenous immunoglobulin market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to intravenous immunoglobulin market.

IVIG Market

Globally North America dominated the market for intravenous immunoglobulin in 2015 with highest market share due to higher awareness about intravenous immunoglobulin coupled with developed medical and healthcare establishment in the region. North America was followed by Europe and Asia-Pacific as the second and third largest regional market respectively, for intravenous immunoglobulin. However, Asia-Pacific is expected to be fastest growing regional segment during the period of study due to fast growing healthcare setup in the region especially in India and China along with growing intravenous immunoglobulin therapy in this region.
  • This report on global intravenous immunoglobulin covers different applications of intravenous immunoglobulin therapy, and also classifies the global intravenous immunoglobulin market based on the basis of route of administration and clinical trial phase and market size in various geographical regions.
  • On the basis of delivery method of the intravenous immunoglobulin, this report is segmented into two major segments as follows: Intravenous, Subcutaneous
  • This reports is also classified on the basis of applications of intravenous immunoglobulin therapy, based on this global intravenous immunoglobulin therapy market is classified into ten major segments as follows: Hypogammaglobulinemia, CIDP, Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome and others
  • This report also covers intravenous immunoglobulin therapy market on the basis of clinical trial outlooks, major segments covered in this report are as follows:  IgG, IgA, IgM, IgE and IgD
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for intravenous immunoglobulin  in each of the region.

This report identifies all the major companies operating in the global intravenous immunoglobulin market. Some of the major companies’ profiles in detail are as follows:
  • Baxter International Inc.
  • China Biologics Products, Inc.
  • Biotest AG
  • Octapharma AG
  • LFB Biotechnologies
1. Intravenous Immunoglobulin – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Intravenous Immunoglobulin – Market Forces
   4.1. Drivers
      4.1.1. Rising reported of immunodeficiency diseases
      4.1.2. Increasing penetration of immunoglobulin replacement therapy
   4.2. Restraints
      4.2.1. Cost of IVIG therapy
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Intravenous Immunoglobulin – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Intravenous Immunoglobulin  Market, By Application
   6.1. Hypogammaglobulinemia
   6.2. CIDP
   6.3. Immunodeficiency diseases
   6.4. Congenital AIDS
   6.5. Chronic Lymphocytic Leukemia
   6.6. Myasthenia Gravis
   6.7. Multifocal Motor Neuropathy
   6.8. ITP
   6.9. Kawasaki Disease
   6.10. Guillain-Barre Syndrome
   6.11. Others
7. Intravenous Immunoglobulin  Market, By Route of Administration
   7.1. Intravenous
   7.2. Subcutaneous
8. Intravenous Immunoglobulin  Market, By Clinical Trial Phase
   8.1. IgG
   8.2. IgA
   8.3. IgM
   8.4. IgE
   8.5. IgD
9. Intravenous Immunoglobulin  Market, By Geography
   9.1. Europe
      9.1.1. Germany
      9.1.2. France
      9.1.3. Italy
      9.1.4. Spain
      9.1.5. Russia
      9.1.6. U.K.
      9.1.7. Rest of Europe
   9.2. Asia Pacific
      9.2.1. China
      9.2.2. India
      9.2.3. Japan
      9.2.4. South Korea
      9.2.5. Rest of Asia-Pacific
   9.3. North America
      9.3.1. U.S.
      9.3.2. Canada
      9.3.3. Mexico
   9.4. Rest of the World (RoW)
      9.4.1. Brazil
      9.4.2. Rest of RoW
10. Intravenous Immunoglobulin – Market Entropy
   10.1. Expansion
   10.2. Technological Developments
   10.3. Merger & Acquisitions, and Joint Ventures
   10.4. Supply- Contract
11. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
   11.1. Baxter International Inc.
   11.2. China Biologics Products, Inc.
   11.3. Biotest AG
   11.4. Octapharma AG
   11.5. LFB Biotechnologies
   11.6. Grifols SA
   11.7. Kedrion Biopharma
   11.8. Changchun Bio
   11.9. CSL Behring
   11.10. Hualan Biological Engineering Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix

   12.1. Abbreviations
   12.2. Sources
   12.3. Research Methodology
   12.4. Expert Insights
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll